title: AttenuatedListeria monocytogenesreprograms M2-polarized tumor-associated macrophages in ovarian cancer leading to iNOS-mediated tumor cell lysis.
abstract: A principal mechanism by which tumors evade immune-mediated elimination is through immunosuppression. Previous approaches to tumor immunotherapy have focused on modifying the immunosuppressive environment with immune checkpoint inhibitors, cytokine therapy, and other modalities with the intent to generate T-cell based anti-tumor immunity. We hypothesized that transformation of the suppressive ovarian cancer microenvironment could be achieved by introduction of the attenuated ΔactA/ΔinlB strain of Listeria monocytogenes. ΔactA/ΔinlB introduced into the microenvironment of the aggressive ID8-Defb29/Vegf-A murine ovarian carcinoma is preferentially phagocytosed by tumor-associated macrophages (TAMs) and reprograms that population from one of suppression to immunostimulation. TAMs in the peritoneum upregulated their co-stimulatory molecules CD80 and CD86, increased transcription of inflammatory cytokines, and downregulated transcription of suppressive effector molecules. Surprisingly, therapeutic benefit was not mediated by T- or NK-cell activity. ΔactA/ΔinlB-induced repolarization of TAMs activated direct tumor cell lysis via Nos2 production of nitric oxide. Modulation of the immunosuppressive nature of the ID8-Defb29/Vegf-A microenvironment, specifically by reprogramming of the TAM suppressive population from M2 to M1 polarization, is critical for our observed immune-mediated survival benefit.
authors.affiliation: Department of Microbiology and Immunology; The Geisel School of Medicine at Dartmouth; Lebanon, NH USA.
authors.forename: Patrick H
authors.initials: PH
authors.lastname: Lizotte
authors.affiliation: Department of Microbiology and Immunology; The Geisel School of Medicine at Dartmouth; Lebanon, NH USA.
authors.forename: Jason R
authors.initials: JR
authors.lastname: Baird
authors.affiliation: Department of Microbiology and Immunology; The Geisel School of Medicine at Dartmouth; Lebanon, NH USA.
authors.forename: Cynthia A
authors.initials: CA
authors.lastname: Stevens
authors.affiliation: Aduro BioTech, Inc.; Berkeley, CA USA.
authors.forename: Peter
authors.initials: P
authors.lastname: Lauer
authors.affiliation: Department of Microbiology and Immunology; The Geisel School of Medicine at Dartmouth; Lebanon, NH USA ; Norris Cotton Cancer Center; Lebanon, NH USA.
authors.forename: William R
authors.initials: WR
authors.lastname: Green
authors.affiliation: Aduro BioTech, Inc.; Berkeley, CA USA.
authors.forename: Dirk G
authors.initials: DG
authors.lastname: Brockstedt
authors.affiliation: Department of Microbiology and Immunology; The Geisel School of Medicine at Dartmouth; Lebanon, NH USA ; Norris Cotton Cancer Center; Lebanon, NH USA.
authors.forename: Steven N
authors.initials: SN
authors.lastname: Fiering
keywords: Listeria; immunosuppression; immunotherapy; ovarian cancer; tumor-associated macrophages
references.citation: Cancer Res. 2009 Jul 15;69(14):5860-6
references.pmid: 19584282
references.citation: Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13832-7
references.pmid: 15365184
references.citation: J Transl Med. 2013 Jun 13;11:147
references.pmid: 23763830
references.citation: J Immunol. 2007 Dec 1;179(11):7376-84
references.pmid: 18025181
references.citation: Int J Cancer. 2009 Jul 15;125(2):367-73
references.pmid: 19378341
references.citation: Nat Med. 2004 Sep;10(9):950-8
references.pmid: 15334073
references.citation: J Exp Med. 1982 Jun 1;155(6):1623-37
references.pmid: 6978922
references.citation: J Immunol. 2009 May 1;182(9):5537-46
references.pmid: 19380802
references.citation: Blood. 2007 Dec 15;110(13):4319-30
references.pmid: 17848619
references.citation: Clin Cancer Res. 2012 Feb 1;18(3):858-68
references.pmid: 22147941
references.citation: Immunobiology. 2013 Jan;218(1):28-39
references.pmid: 22445076
references.citation: Cancer Res. 2007 Oct 15;67(20):10058-66
references.pmid: 17942940
references.citation: Int J Cancer. 2014 Jan 1;134(1):32-42
references.pmid: 23784932
references.citation: Immunity. 2003 Jul;19(1):59-70
references.pmid: 12871639
references.citation: J Exp Med. 2008 Jun 9;205(6):1261-8
references.pmid: 18490490
references.citation: N Engl J Med. 2006 Jan 5;354(1):34-43
references.pmid: 16394300
references.citation: Science. 2011 Mar 25;331(6024):1612-6
references.pmid: 21436454
references.citation: Nat Rev Immunol. 2010 Jun;10(6):453-60
references.pmid: 20467425
references.citation: J Immunol. 2012 Jun 15;188(12):6389-98
references.pmid: 22586039
references.citation: Cancer Res. 2013 Jul 1;73(13):3842-51
references.pmid: 23704211
references.citation: Cancer Res. 2007 Sep 15;67(18):8900-5
references.pmid: 17875732
references.citation: J Immunol. 2012 Feb 1;188(3):1117-24
references.pmid: 22184722
references.citation: Neoplasia. 2009 Jun;11(6):564-73, 1 p following 573
references.pmid: 19484145
references.citation: J Exp Med. 2011 Mar 14;208(3):577-92
references.pmid: 21383057
references.citation: JAMA. 2011 Feb 2;305(5):487-94
references.pmid: 21285426
references.citation: Trends Immunol. 2002 Nov;23(11):549-55
references.pmid: 12401408
references.citation: Infect Immun. 2006 Nov;74(11):6387-97
references.pmid: 16954391
references.citation: Vaccine. 2009 Jun 19;27(30):3975-83
references.pmid: 19389451
references.citation: PLoS Pathog. 2012;8(6):e1002763
references.pmid: 22719255
references.citation: Methods. 2001 Dec;25(4):402-8
references.pmid: 11846609
references.citation: J Clin Oncol. 2012 Jun 10;30(17):2039-45
references.pmid: 22529265